From the Meso Foundation Staff

A Message from the CEO

by Melinda Kotzian, Chief Executive Officer, Mesothelioma Applied Research Foundation
Over the last 24 hours, news broke that some cancer charities raised funds and did not use the money responsibly. The Meso Foundation has always prided itself on transparency when it comes to financials. We voluntarily subject our organization to an audit every year and then submit […]

Introducing Muriel Evans-Buck, Director of Development

Aiming to strengthen its major fundraising efforts, the Meso Foundation added Muriel Evans-Buck as the Director of Development. Muriel started on December 1, 2014 bringing with her extensive experience in professional fundraising.
Muriel’s career has included senior positions in development with several national organizations. She has worked for Sickle Cell Disease Association of America and Campaign […]

We will miss you, Jessica!

Dear friends,
We wanted to share with you the news that our director of government affairs, Jessica Barker, will be, for personal reasons, leaving her position at the Meso Foundation at the end of August. During the three years spent at the Foundation, Jessica has been instrumental in advancing the meso community’s issues on Capitol Hill. […]

Results of the NGR-hTNF Mesothelioma Clinical Trial Now Available

Today, MolMed, an Italian pharmaceutical company, released results from its NGR-hTNF for mesothelioma clinical trial. While the trial, which enrolled 400 pleural mesothelioma patients, demonstrated no increases in overall survival of the entire population, it did show an improvement in survival for those patients with a poorer prognosis and whose disease had progressed between first-line […]

Meet the Mesothelioma Experts: Defactinib, a New Investigational Agent for Mesothelioma

On April 8 at 9 PM Eastern time, the Mesothelioma Applied Research Foundation (Meso Foundation) will hold a new installment of its ‘Meet the Experts’ series, featuring Dr. Joanna C. Horobin, the Chief Medical Officer at Verastem, Inc., who will discuss the company’s latest investigational agent, defactinib, which is being developed for use in patients with pleural […]